Which country developed and produced larotrectinib?

Larotrectinib is a targeted treatment drug targeting NTRK gene fusion, developed and produced by the American biopharmaceutical company Loxo Oncology (later acquired by Eli Lilly). This drug is the world's first "tumor-free" targeted drug approved for the treatment of all NTRK fusion-positive solid tumors, marking a new stage of precision cancer treatment that is gene-driven and has nothing to do with tumor types.

Larotrectinib was first granted accelerated approval by the U.S. FDA in 2018 for the treatment of children and adults with locally advanced or metastatic solid tumors who are NTRK fusion-positive, have no known acquired resistance mutations, and have no satisfactory alternative treatment options. This method of classifying treatment according to "gene mutation" rather than "cancer location" is considered a major innovation in the concept of cancer treatment. As an American original drug, larotrectinib has undergone rigorous clinical trial verification during the research and development process, showing broad-spectrum anti-tumor activity and good tolerability.

With the continuous accumulation of clinical data, larotrectinib has successively obtained marketing approval in many countries and regions, including the European Union, Canada, Japan and other countries. Although its indication involves a relatively small patient population, its high response rate in NTRK fusion-positive tumors has attracted much attention. Especially in patients with certain rare cancer types such as infantile fibrosarcoma, thyroid cancer and salivary gland cancer, larotrectinib has also shown significant efficacy.

Currently, larotrectinib has not yet been officially launched in mainland China. If domestic patients want to use the drug, they generally need to obtain it through overseas channels. Nonetheless, as my country continues to pay more attention to "precision-targeted drugs for rare mutations", larotrectinib is expected to be introduced at an accelerated pace in the future. As an innovative targeted drug developed and produced in the United States, the success of larotrectinib has also encouraged global pharmaceutical companies to continue exploring and investing in the "tumor-free" treatment field.

Reference materials:https://www.vitrakvi.com/